PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
Oasis Publishers

Press Release

Share      Blog

Receive press releases from Oasis Publishers: By Email PDF Version RSS Feeds:

Bad Cholesterol May be Our Best Friend by Uffe Ravnskov from Oasis Publishers


Bad Cholesterol May be Our Best Friend by Uffe Ravnskov from Oasis Publishers
New York, NY, November 03, 2018 --(PR.com)-- Uffe Ravnskov and his team from Oasis Publishers announces ground-breaking research findings that counters the basic argument or general belief that bad cholesterol leads to heart diseases.

Cholesterol is a fatty lipid found in all cells in our body and it is vital for the normal functioning of the body. It is produced within our body and has important natural functions like digesting foods, producing hormones, and generating vitamin D. There are two types of cholesterol - LDL (low-density lipoproteins, generally termed bad cholesterol) and HDL (high-density lipoproteins, generally termed good cholesterol).

These research findings prove that the common argument against bad cholesterol and the support from drug companies in this regard are invalid. He has proved that the research studies that link cholesterol with heart diseases are compromised by misleading statistics, exclude unsuccessful trials, minimize the side effects of cholesterol lowering, and ignore the contradictory observations from independent investigators.

In 2016, Uffe Ravnskov and his team published a review of 19 studies where over 68,000 elderly people were studied over the years measured for bad LDL cholesterol. It was observed from the study that those with the highest values of LDL cholesterol lived the longest. It was also found that those not taking statin treatment lived the longest.

Even though there were many criticisms on these findings, there was no research finding which proved otherwise. The only supporting research was the one sponsored by the drug industry, where three reviews were published that support the benefit of statins. In the paper named “LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature” published in Expert Review of Clinical Pharmacology, He countered the validity of the findings presented in these three reviews, taking into account the fact that these reviews ignored any other contradictory reports against cholesterol, by any independent scholar.

More than a dozen studies, the first of it published 80 years ago, has shown that people with low cholesterol became just as atherosclerotic as people with high cholesterol. He also proved that lipid hypothesis is the greatest and costliest medical scam ever.

The research findings from Uffe Ravnskov and his team also observes that in an American study of more than 14000 people with acute myocardial infarction, it was seen that their acute myocardial infarction was lower than normal. In a follow-up study three years later, it was observed that total mortality among those with the lowest LDL-cholesterol was twice as high compared to those with high cholesterol.

Another major observation is that lowering cholesterol levels does not prevent heart disease. He re-observed the exposure-response model used in statin trials by Michael G. Silverman and his eight co-authors from various American Universities. The exposure-response model works on the basis that lower the cholesterol, lower the heart disease. He found that the above researchers have excluded at least 11 unsuccessful trials with the opposite result, and if calculated together, no exposure-response is present. A similar finding was also made by analysing the study from the European Atherosclerosis Society Consensus Panel consisting of 26 authors.

He concludes that in most statin trials, the outcome has been misleading because the authors have used relative risk reduction rather than absolute risk reduction. Uffe Ravnskov observes that this study has referred to a previous analysis of 27 statin trials performed by the Cholesterol Treatment Trialists.

In all the statin trials, the directors have tested the drug on all participants in a short run-in period before the start, and excluded those who suffered from side effects. Statin may cause many serious side effects, the most common of which is muscular damage. Independent researchers have observed that statin treatment may cause heart failure, diabetes, cataract, hearing loss, impotency, memory loss, cognitive impairments, depression, suicidal ideation, Parkinson's disease, nerve damage, and cancer.

Through extensive analysis of different research studies, Uffe Ravnskov and his team establishes that high cholesterol is beneficial, and apart from the bodily functions, high cholesterol has another important part to play. LDL, the molecular submarine that transports cholesterol around in the blood, help the immune system by adhering to and inactivating almost all types of microorganisms and their toxic products.

It is found that after the New Clinical Trial Regulations (2004-2005) in Europe and the US, it was mandatory that all trial data had to be made public. Uffe Ravnskov and team finds that since 2005, no statin trial has been successful, which questions the validity of previous researches that used statin trials to confirm the association between cholesterol with heart diseases.
Contact Information
Oasis Publishers
Uffe Ravnskov
+9966967980
Contact
www.oasispub.org

Click here to view the list of recent Press Releases from Oasis Publishers
Promote Your Business